nutrients-logo

Journal Browser

Journal Browser

Nutrition Therapy for Liver and Associated Metabolic Diseases

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Clinical Nutrition".

Deadline for manuscript submissions: 15 June 2026 | Viewed by 1387

Special Issue Editor


E-Mail Website
Guest Editor
Department of Food & Nutrition, College of Human Ecology, Kyung Hee University, 26, Kyungheedae-ro, Hoegi-dong, Dongdaemun-gu, Seoul 02447, Republic of Korea
Interests: iron and zinc metabolism; vitamin A and carotenoids functions; niver diseases; metabolic disorders; nutrient-gene interaction; chrononutrition

Special Issue Information

Dear Colleagues,

Liver diseases encompass a wide range of conditions that affect the liver and its function and are closely associated with a number of metabolic and systemic disorders that can have a significant impact on overall health. The prevalence of liver disease is increasing worldwide.

This Special Issue, entitled "Nutrition Therapy for Liver and Associated Metabolic Diseases", aims to address the critical role of nutritional interventions in the prevention, management, and potential reversal of liver-related health conditions. Key topics to be explored include the preventive effects of nutrients and bioactive compounds in foods against the development of liver and related diseases, the impact of macronutrient and calorie intake on liver function, the role of vitamins and minerals in the management of liver disease, and the therapeutic potential of phytochemicals and probiotics. Both preclinical animal studies and clinical trials will be considered to provide a robust understanding of the role of diet in liver disease. In addition, reviews that provide a relevant scientific contribution will also be considered.

Prof. Dr. Jayong Chung
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liver disease
  • metabolic-dysfunction-associated liver disease (MAFLD)
  • alcoholic liver disease (ALD)
  • diet
  • macronutrient
  • calorie
  • micronutrient
  • bioactive compound

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

24 pages, 4082 KB  
Article
Agrimonia pilosa Extract Alleviates CDAHFD-Induced Non-Alcoholic Steatohepatitis and Fibrosis in Mice
by Min-Jeong Jo, Sun Jin Hwang, Myung-Gi Seo, Jun-Ho Lee, Jae Woo Lee, Yoon Hee Kim, Yongduk Kim and Sang-Joon Park
Nutrients 2026, 18(1), 42; https://doi.org/10.3390/nu18010042 - 22 Dec 2025
Viewed by 869
Abstract
Background: Non-alcoholic steatohepatitis (NASH) lacks approved pharmacotherapies despite affecting approximately 25% of the global population. Agrimonia pilosa, a traditional herb with anti-inflammatory and antioxidant properties, remains unexplored for NASH treatment. Objective: This study investigated the hepatoprotective effects and mechanisms of Agrimonia pilosa [...] Read more.
Background: Non-alcoholic steatohepatitis (NASH) lacks approved pharmacotherapies despite affecting approximately 25% of the global population. Agrimonia pilosa, a traditional herb with anti-inflammatory and antioxidant properties, remains unexplored for NASH treatment. Objective: This study investigated the hepatoprotective effects and mechanisms of Agrimonia pilosa extract (APE) in NASH models. Methods: HepG2 cells were treated with free fatty acids (0.125 mM) and APE (+12.5–50 μg/mL). C57BL/6J mice received a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) for 12 weeks with APE (25–100 mg/kg/day), silymarin (100 mg/kg/day), or luteolin (20 mg/kg/day). Lipid accumulation, liver enzymes, histopathology, and molecular markers were assessed. Results: APE dose-dependently reduced lipid accumulation in FFA-treated cells, suppressed lipogenic factors (SREBF1, CEBPA, and PPARG), and upregulated fatty acid oxidation enzymes (CPT1A and PPARA) via AMPK/SIRT1 activation. In NASH mice, APE (100 mg/kg) significantly decreased serum ALT (160.0 ± 49.1 vs. 311.2 ± 66.7 U/L) and AST (96.0 ± 18.7 vs. 219.0 ± 55.7 U/L, p < 0.001), reduced hepatic macrophage infiltration by 68%, and substantially attenuated inflammatory markers (Ccl2, Tnf, and IL6), oxidative stress indicators (NRF2, HMOX1, and CYBB), and fibrogenic markers (ACTA2, COL1A1, and TGFB1) by 83–85% (p < 0.001). Collagen deposition decreased from 5.63 ± 0.39% to 1.54 ± 0.03% (p < 0.001). Conclusions: APE exerts potent hepatoprotective effects through multi-targeted modulation of lipid metabolism, inflammation, oxidative stress, and fibrosis via AMPK/SIRT1 pathway activation, supporting its potential as a natural therapeutic intervention for NASH. Full article
(This article belongs to the Special Issue Nutrition Therapy for Liver and Associated Metabolic Diseases)
Show Figures

Figure 1

Back to TopTop